Platelet derived growth factor BB is a ligand for dermatan sulfate chain(s) of small matrix proteoglycans from normal and fibrosis affected fascia.
Structural requirements of the short isoform of platelet derived growth factor BB (PDGF-BB) to bind dermatan sulfate (DS)/chondroitin sulfate (CS) are unknown. Meanwhile the interaction may be important for tissue repair and fibrosis which involve both high activity of PDGF-BB and matrix accumulation of DS. We examined by the solid phase assay the growth factor binding to DS chains of small proteoglycans from various fasciae as well as to standard CSs. Before the assay a structural analysis of DSs and CSs was accomplished involving the evaluation of their epimerization and/or sulfation patterns. In addition, in vivo acceptors for PDGF-BB in fibrosis affected fascia were detected. PDGF-BB binding sites on DSs/CSs are located in long chain sections with the same type of hexuronate isomer however without any apparent preference to glucuronate or iduronate residues. Alternatively, the interaction seems to involve two shorter DS chain sections assembling disaccharides with the same type of hexuronate isomer which are separated by disaccharide(s) with another hexuronate one. Moreover, DS/CS affinity to the growth factor most probably depends on an accumulation of di-2,4-O-sulfated disaccharides in binding site while the presence of 6-O-sulfated N-acetyl-galactosamine residues rather attenuates the binding. All examined fascia DSs and standard CSs showed significant PDGF-BB binding capability with the highest affinity found for normal palmar fascia decorin DS. In fibrosis affected palmar fascia DS/CS proteoglycans are able to form with PDGF-BB supramolecular complexes also including other matrix components such as type III collagen and fibronectin which bind the growth factor covalently. Our results suggest that DS chains of fascia matrix small PGs may regulate PDGF-BB availability leading to restriction of fibrosis associated with Dupuytren's disease or to control of normal fascia repair.
Koźma
Ewa M
EM
Department of Clinical Chemistry and Laboratory Diagnostics, Medical University of Silesia, Jedności 8, 41-200 Sosnowiec, Poland. mkozma@sum.edu.pl
Wisowski
Grzegorz
G
Olczyk
Krystyna
K
D000077214:Becaplermin; D003871:Dermatan Sulfate / Q000737:chemistry*; D005205:Fascia / Q000737:chemistry* / Q000473:pathology; D005260:Female; D005355:Fibrosis / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010715:Phosphatidylglycerols / Q000737:chemistry; D010982:Platelet-Derived Growth Factor / Q000032:analysis* / Q000737:chemistry; D011509:Proteoglycans / Q000737:chemistry*; D020574:Proto-Oncogene Proteins c-sis; D012710:Serum Albumin, Bovine
D010715:Phosphatidylglycerols; D010982:Platelet-Derived Growth Factor; D011509:Proteoglycans; D020574:Proto-Oncogene Proteins c-sis; D000077214:Becaplermin; D003871:Dermatan Sulfate; D012710:Serum Albumin, Bovine; C084352:distearoyl phosphatidylglycerol